PPARA and lung adenocarcinoma: Previous studies have reported that PPAR, an anti-inflammatory molecule with a potent, could promote tumor proliferation, angiogenesis, inflammation, and metastasis in lung adenocarcinoma (Reka et al., 2011; Ammu et al., 2019), suggesting that it is a vital and potential therapeutic target for lung adenocarcinoma.